Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

The safety and efficacy of dipeptidyl peptidase-4 (DPP4) inhibitors as monotherapy or in combination with other oral antidiabetic agents or basal insulin are well established. DPP4 inhibitors stimulate glucose-dependent insulin secretion and inhibit glucagon production. As monotherapy, they reduce t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez-Peralta, Fernando, Abreu, Cristina, Gomez-Rodriguez, Sara, Barranco, Rafael J., Umpierrez, Guillermo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167285/
https://www.ncbi.nlm.nih.gov/pubmed/30117055
http://dx.doi.org/10.1007/s13300-018-0488-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167285/
https://www.ncbi.nlm.nih.gov/pubmed/30117055
http://dx.doi.org/10.1007/s13300-018-0488-z

Ejemplares similares